Users Stopping Weight-Loss Jabs Gain Back Weight Four Times Faster Compared to People Using Diet and Exercise

A recent study reveals that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who stop conventional lifestyle programs.

Research printed in a major medical journal demonstrates that while overweight individuals can lose substantial amounts of their body weight while on the medication, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.

"Users buying such treatments should be informed of the risk of quick weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.

That rate of recovery implies a reversion to pre-treatment mass in about 18 months.

Comparing Approaches

The analysis, which examined 37 of studies involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.

Researchers note that people who shed pounds through diet and exercise typically experience a less rapid creep back—approximately 0.1 kg a month—once they finish.

The Reason for the Quick Regain

Nutrition scientists believe the mode of action of the injections explains the amplified weight return.

GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Sustained high doses of GLP-1 levels far above than normal may cause the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.

"Withdrawal of this medication means hunger is uncontrolled, making overeating much more probable."

A Lifelong Condition?

The NHS recommend the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.

Many experts say that, due to the high risk of relapse, the treatment might need to be ongoing.

This opinion is supported by pharmaceutical companies, who note that the results "highlight the long-term nature of obesity," similar to managing conditions like diabetes.

Patient Experiences

Users who have come off the medication describe a powerful return of appetite.

"It felt as if something that goes on and I was suddenly extremely hungry," recalled a patient.

This challenge is exacerbated if individuals have not developed sustainable dietary or behavioural modifications during treatment.

Significant Use

Figures suggest that a significant number of people in the UK have used these injections in the last 12 months, with desire being substantial.

• Adoption is higher among females than males.
• The 40s and 50s age group shows the highest level of interest.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

Ultimately, researchers caution that while the jabs are powerful tools for shedding pounds, they are not a permanent fix and maintained weight loss hinges on ongoing lifestyle support.